Breathing New Life into Pulmonary Arterial Hypertension Treatment: Targeting Serotonin Synthesis with an Inhalation Approach
- PMID: 39918913
- PMCID: PMC12334879
- DOI: 10.1165/rcmb.2025-0040ED
Breathing New Life into Pulmonary Arterial Hypertension Treatment: Targeting Serotonin Synthesis with an Inhalation Approach
Comment on
-
Inhalation of the Novel Tryptophan Hydroxylase 1 Inhibitor TPT-004 Alleviates Pulmonary Arterial Hypertension.Am J Respir Cell Mol Biol. 2025 Aug;73(2):288-298. doi: 10.1165/rcmb.2024-0365OC. Am J Respir Cell Mol Biol. 2025. PMID: 39899532
References
-
- Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, et al. for the International Primary Pulmonary Hypertension Study Group Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med . 1996;335:609–616. - PubMed
-
- Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, et al. Converging evidence in support of the serotonin hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice. Circulation . 2008;117:2928–2937. - PubMed
-
- Morecroft I, Pang L, Baranowska M, Nilsen M, Loughlin L, Dempsie Y, et al. In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension. Cardiovasc Res . 2010;85:593–603. - PubMed
-
- Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med . 2003;168:487–493. - PubMed
-
- Izikki M, Hanoun N, Marcos E, Savale L, Barlier-Mur AM, Saurini F, et al. Tryptophan hydroxylase 1 knockout and tryptophan hydroxylase 2 polymorphism: effects on hypoxic pulmonary hypertension in mice. Am J Physiol Lung Cell Mol Physiol . 2007;293:L1045–L1052. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
